Chennamasetty Subramanyam
Chennamasetty Subramanyam has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- C. Gladis Raja Malar
Vel Tech Engineering College
3 shared publications - Kammela Prasada Rao
Department of Chemistry, Bapatla Engineering College
3 shared publications - Anuradha Vejendla
Department of Chemistry, Vignan Degree College, Guntur, India
2 shared publications - Gopisetty Ratala Satyanarayana
Sir.C.R.Reddy College
2 shared publications - Vedula Naga Lakshmi
Department of Chemistry, Ch.S.D.St.Theresa’s College for Women (A)
2 shared publications Bogiri Sujatha
Department of Chemistry, Y. A. Govt. Degree College for Women
1 shared publication
Latest Publications
- 19 February 2026
- Published by Taylor & Francis in Phosphorus, Sulfur, and Silicon and the Related Elements
- Vol. 201 (6) , 825-839
Design and synthesis of new bis(α-aminophosphonates) via ultrasound-driven nano-BF 3 ·SiO 2 catalysis targeting α-amylase inhibition: In silico ADME and molecular docking study
- 19 February 2026
- Published by Taylor & Francis in Phosphorus, Sulfur, and Silicon and the Related Elements
- Vol. 201 (6) , 825-839
Design and synthesis of new bis(α-aminophosphonates) via ultrasound-driven nano-BF 3 ·SiO 2 catalysis targeting α-amylase inhibition: In silico ADME and molecular docking study
- 30 June 2025
- Published by ACG Publications in Organic Communications
- Vol. 18 (2) , 60-82
Nano-ZnO catalyzed microwave synthesis of novel α-aminophosphonates: anti-diabetic potential via molecular docking, ADMET analysis, and α-amylase and α-glucosidase inhibition studies
A more efficient and environmentally friendly approach has been developed for synthesizing α-aminophosphonates through the Kabachnik-Fields (K-F), catalyzed by nano-ZnO in a solvent-free environment, utilizing microwave irradiation. Before synthesis, each compound underwent in silico ADMET analysis and molecular docking to assess drug-like characteristics and their potential to inhibit α-amylase. The structure of the newly synthesized compounds was validated using spectroscopic analysis, and their in vitro inhibitory effects on α-amylase and α-glucosidase were assessed. Among the compounds 8g (IC50, 99.2±0.5 μg/mL), 8i (IC50, 101.2±0.3 μg/mL), 8e (IC50, 102.1±0.4 μg/mL) and 8j (IC50, 103.4±0.4 μg/mL) containing anthracen-9-ylamino, phenanthren-9-ylamino, 2-oxo-2H-chromen-6-yl)amino and 2-benzoylphenyl)amino moieties respectively, exhibited the highest inhibitory activity on α-amylase, superior to the reference compound acarbose (IC50, 104.5±0.1 μg/mL). The remaining compounds demonstrated moderate to good enzyme inhibition. 8c bearing with 4-fluorophenyl substituent (IC50, 88.4±0.7 μg/mL), 8e (IC50, 90.0±0.4 μg/mL) bearing with 2-oxo-2H-chromen-6-yl substituent and 8d (IC50, 91.1±0.9 μg/mL) bearing with 2-methylbenzo[d]oxazol-5-yl moiety have shown the highest inhibitory activity on α-glucosidase than the reference drug, Acarbose ((IC50, 93.1±0.8 μg/mL). The remaining compounds exhibited moderate to good inhibition on the enzyme with IC50 ranging 94.5±0.9 to 141.4±0.7 μg/mL.rnrn
- 30 June 2025
- Published by ACG Publications in Organic Communications
- Vol. 18 (2) , 60-82
Nano-ZnO catalyzed microwave synthesis of novel α-aminophosphonates: anti-diabetic potential via molecular docking, ADMET analysis, and α-amylase and α-glucosidase inhibition studies
A more efficient and environmentally friendly approach has been developed for synthesizing α-aminophosphonates through the Kabachnik-Fields (K-F), catalyzed by nano-ZnO in a solvent-free environment, utilizing microwave irradiation. Before synthesis, each compound underwent in silico ADMET analysis and molecular docking to assess drug-like characteristics and their potential to inhibit α-amylase. The structure of the newly synthesized compounds was validated using spectroscopic analysis, and their in vitro inhibitory effects on α-amylase and α-glucosidase were assessed. Among the compounds 8g (IC50, 99.2±0.5 μg/mL), 8i (IC50, 101.2±0.3 μg/mL), 8e (IC50, 102.1±0.4 μg/mL) and 8j (IC50, 103.4±0.4 μg/mL) containing anthracen-9-ylamino, phenanthren-9-ylamino, 2-oxo-2H-chromen-6-yl)amino and 2-benzoylphenyl)amino moieties respectively, exhibited the highest inhibitory activity on α-amylase, superior to the reference compound acarbose (IC50, 104.5±0.1 μg/mL). The remaining compounds demonstrated moderate to good enzyme inhibition. 8c bearing with 4-fluorophenyl substituent (IC50, 88.4±0.7 μg/mL), 8e (IC50, 90.0±0.4 μg/mL) bearing with 2-oxo-2H-chromen-6-yl substituent and 8d (IC50, 91.1±0.9 μg/mL) bearing with 2-methylbenzo[d]oxazol-5-yl moiety have shown the highest inhibitory activity on α-glucosidase than the reference drug, Acarbose ((IC50, 93.1±0.8 μg/mL). The remaining compounds exhibited moderate to good inhibition on the enzyme with IC50 ranging 94.5±0.9 to 141.4±0.7 μg/mL.rnrn
- 15 October 2023
- Published by Taylor & Francis in Synthetic Communications
- Vol. 53 (23) , 2041-2060
Ultrasound mediated nano ZnO catalyzed synthesis of new α -aminophosphonates as potential anti-diabetic agents; an in silico ADMET, molecular docking study, α -amylase and α -glucosidase inhibitory activity
- 15 October 2023
- Published by Taylor & Francis in Synthetic Communications
- Vol. 53 (23) , 2041-2060
Ultrasound mediated nano ZnO catalyzed synthesis of new α -aminophosphonates as potential anti-diabetic agents; an in silico ADMET, molecular docking study, α -amylase and α -glucosidase inhibitory activity
- 14 April 2023
- Published by Taylor & Francis in Phosphorus, Sulfur, and Silicon and the Related Elements
- Vol. 198 (10) , 808-821
In silico molecular docking study and nano TiO 2 -SiO 2 catalyzed microwave facilitated synthesis of new bis( α -aminophosphonates) as potential anti-diabetic agents
In the present work, we have developed a greener approach to synthesize a series of novel bis(α-aminophosphonates) (bis(α-Aps)) via a microwave-mediated nano TiO2-SiO2 catalyzed Kabachnik-Fields (K-F) reaction under solvent-free conditions. An in silico molecular docking analysis was performed on all the designed molecules prior to their synthesis to get insight into their capacity to block the enzymes, α-amylase (PDB ID:3IJ8) and α-glucosidase (PDB ID:1OBB). The molecules with significant binding affinity were synthesized and spectroscopically analyzed to confirm their structure. They were screened further in vitro for their inhibitory activity on the target enzymes. When compared with the reference drug, the compounds diethyl[(2H‐1,3‐benzodioxol‐5‐yl)[(6‐{[(2H‐1,3‐benzodioxol‐5‐yl)(diethoxyphosphoryl)-methyl]amino}‐10,10‐dioxo‐9H‐10λ6‐thioxanthen‐3‐yl)amino]-methyl]phosphonate (4h), diethyl [(anthracen-9-yl)[(6-{[(anthracen-9-yl)(diethoxyphosphoryl)methyl]amino}-10,10-dioxo-9H-10λ6-thioxanthen-3-yl)amino]-methyl]phosphonate (4i) have shown greater inhibition, and diethyl{[(6‐{[(diethoxyphosphoryl)(phenyl)methyl]amino}‐10,10‐dioxo‐9H‐10λ6‐thioxanthen‐3‐yl)amino](phenyl)methyl}phosphonate (4a), diethyl {[(6-{[(diethoxyphosphoryl)(4-hydroxy-3-nitrophenyl)methyl]amino}-10,10-dioxo-9H-10λ6-thioxanthen-3-yl)amino](4-hydroxy-3-nitrophenyl)methyl}phosphonate (4e) have shown equal inhibition against the α-amylase enzyme. Compounds diethyl{[(6‐{[(diethoxyphosphoryl)(phenyl)methyl]amino}‐10,10‐dioxo‐9H‐10λ6‐thioxanthen‐3‐yl)-amino](phenyl)methyl}phosphonate (4a), diethyl[(2H‐1,3‐benzodioxol‐5‐yl)[(6‐{[(2H‐1,3‐benzodioxol‐5‐yl)(diethoxyphosphoryl)methyl]amino}‐10,10‐dioxo‐9H‐10λ6‐thioxanthen‐3‐yl)amino]methyl]phosphonate (4h), and diethyl [(anthracen-9-yl)[(6-{[(anthracen-9-yl)(diethoxyphosphoryl)methyl]amino}-10,10-dioxo-9H-10λ6-thioxanthen-3-yl)amino]-methyl]phosphonate (4i) have shown superior inhibition and diethyl{[(6‐{[(diethoxyphosphoryl)(naphthalen‐1‐yl)methyl]amino}‐10,10‐dioxo‐9H‐10λ6‐thioxanthen‐3‐yl)amino](naphthalen‐1‐yl)methyl}phosphonate (4 g) has shown equal inhibition against the α-glucosidase enzyme. All the remaining compounds displayed modest to good inhibition when compared with the reference drug, Acarbose. Graphical Abstract
- 14 April 2023
- Published by Taylor & Francis in Phosphorus, Sulfur, and Silicon and the Related Elements
- Vol. 198 (10) , 808-821
In silico molecular docking study and nano TiO 2 -SiO 2 catalyzed microwave facilitated synthesis of new bis( α -aminophosphonates) as potential anti-diabetic agents
In the present work, we have developed a greener approach to synthesize a series of novel bis(α-aminophosphonates) (bis(α-Aps)) via a microwave-mediated nano TiO2-SiO2 catalyzed Kabachnik-Fields (K-F) reaction under solvent-free conditions. An in silico molecular docking analysis was performed on all the designed molecules prior to their synthesis to get insight into their capacity to block the enzymes, α-amylase (PDB ID:3IJ8) and α-glucosidase (PDB ID:1OBB). The molecules with significant binding affinity were synthesized and spectroscopically analyzed to confirm their structure. They were screened further in vitro for their inhibitory activity on the target enzymes. When compared with the reference drug, the compounds diethyl[(2H‐1,3‐benzodioxol‐5‐yl)[(6‐{[(2H‐1,3‐benzodioxol‐5‐yl)(diethoxyphosphoryl)-methyl]amino}‐10,10‐dioxo‐9H‐10λ6‐thioxanthen‐3‐yl)amino]-methyl]phosphonate (4h), diethyl [(anthracen-9-yl)[(6-{[(anthracen-9-yl)(diethoxyphosphoryl)methyl]amino}-10,10-dioxo-9H-10λ6-thioxanthen-3-yl)amino]-methyl]phosphonate (4i) have shown greater inhibition, and diethyl{[(6‐{[(diethoxyphosphoryl)(phenyl)methyl]amino}‐10,10‐dioxo‐9H‐10λ6‐thioxanthen‐3‐yl)amino](phenyl)methyl}phosphonate (4a), diethyl {[(6-{[(diethoxyphosphoryl)(4-hydroxy-3-nitrophenyl)methyl]amino}-10,10-dioxo-9H-10λ6-thioxanthen-3-yl)amino](4-hydroxy-3-nitrophenyl)methyl}phosphonate (4e) have shown equal inhibition against the α-amylase enzyme. Compounds diethyl{[(6‐{[(diethoxyphosphoryl)(phenyl)methyl]amino}‐10,10‐dioxo‐9H‐10λ6‐thioxanthen‐3‐yl)-amino](phenyl)methyl}phosphonate (4a), diethyl[(2H‐1,3‐benzodioxol‐5‐yl)[(6‐{[(2H‐1,3‐benzodioxol‐5‐yl)(diethoxyphosphoryl)methyl]amino}‐10,10‐dioxo‐9H‐10λ6‐thioxanthen‐3‐yl)amino]methyl]phosphonate (4h), and diethyl [(anthracen-9-yl)[(6-{[(anthracen-9-yl)(diethoxyphosphoryl)methyl]amino}-10,10-dioxo-9H-10λ6-thioxanthen-3-yl)amino]-methyl]phosphonate (4i) have shown superior inhibition and diethyl{[(6‐{[(diethoxyphosphoryl)(naphthalen‐1‐yl)methyl]amino}‐10,10‐dioxo‐9H‐10λ6‐thioxanthen‐3‐yl)amino](naphthalen‐1‐yl)methyl}phosphonate (4 g) has shown equal inhibition against the α-glucosidase enzyme. All the remaining compounds displayed modest to good inhibition when compared with the reference drug, Acarbose. Graphical Abstract
- 20 October 2021
- Published by Taylor & Francis in Phosphorus, Sulfur, and Silicon and the Related Elements
- Vol. 196 (11) , 1010-1017
In silicomolecular docking study, synthesis andα-amylase inhibitory activity evaluation of phosphorylated derivatives of purine
A series of phosphorylated derivatives of purine were synthesized in good yields (88–95%) by the reaction of 2‐chloro‐4‐{[(9H‐purin‐9‐yl)methoxy]methyl}‐1,3,2-λ5‐dioxaphospholan‐2‐one with various heterocyclic amines. In silico molecular docking study was performed for all the designed compounds to assess their potential ability to inhibit the pancreatic α-amylase enzyme. The compounds (6a–j) with good inhibition toward the target enzyme were prompted for the synthesis. Spectroscopic analyses of all the newly synthesized compounds were performed to confirm their structures. In vitro α-amylase inhibitory activity of the synthesized compounds was also carried out using acarbose as a standard drug. The compounds 2‐[(6‐chloro‐1,3‐benzothiazol‐2‐yl)amino]‐4‐{[(9H‐purin‐9‐yl)methoxy]methyl}‐1,3,2λ5‐dioxaphospholan‐2‐one (6j) (IC50, 94.3 ± 0.5 μg/mL) and 1‐methyl‐6‐[(2‐oxo‐4‐{[(9H‐purin‐9‐yl)methoxy]methyl}‐1,3,2λ5‐dioxaphospholan‐2‐yl)amino]‐1,2,3,4‐tetrahydropyrimidine‐2,4‐dione (6f) (IC50, 99.0 ± 0.4 μg/mL) reported the highest inhibition among the synthesized compounds. All the remaining compounds exhibited good to moderate inhibition with IC50 values in the range of 102.9 ± 0.6 to 233.5 ± 0.6 μg/mL when compared with the standard drug, acarbose (IC50, 50.47 ± 0.28 μg/mL). Graphical Abstract
- 20 October 2021
- Published by Taylor & Francis in Phosphorus, Sulfur, and Silicon and the Related Elements
- Vol. 196 (11) , 1010-1017
In silicomolecular docking study, synthesis andα-amylase inhibitory activity evaluation of phosphorylated derivatives of purine
A series of phosphorylated derivatives of purine were synthesized in good yields (88–95%) by the reaction of 2‐chloro‐4‐{[(9H‐purin‐9‐yl)methoxy]methyl}‐1,3,2-λ5‐dioxaphospholan‐2‐one with various heterocyclic amines. In silico molecular docking study was performed for all the designed compounds to assess their potential ability to inhibit the pancreatic α-amylase enzyme. The compounds (6a–j) with good inhibition toward the target enzyme were prompted for the synthesis. Spectroscopic analyses of all the newly synthesized compounds were performed to confirm their structures. In vitro α-amylase inhibitory activity of the synthesized compounds was also carried out using acarbose as a standard drug. The compounds 2‐[(6‐chloro‐1,3‐benzothiazol‐2‐yl)amino]‐4‐{[(9H‐purin‐9‐yl)methoxy]methyl}‐1,3,2λ5‐dioxaphospholan‐2‐one (6j) (IC50, 94.3 ± 0.5 μg/mL) and 1‐methyl‐6‐[(2‐oxo‐4‐{[(9H‐purin‐9‐yl)methoxy]methyl}‐1,3,2λ5‐dioxaphospholan‐2‐yl)amino]‐1,2,3,4‐tetrahydropyrimidine‐2,4‐dione (6f) (IC50, 99.0 ± 0.4 μg/mL) reported the highest inhibition among the synthesized compounds. All the remaining compounds exhibited good to moderate inhibition with IC50 values in the range of 102.9 ± 0.6 to 233.5 ± 0.6 μg/mL when compared with the standard drug, acarbose (IC50, 50.47 ± 0.28 μg/mL). Graphical Abstract
- 23 November 2020
- Published by Taylor & Francis in Phosphorus, Sulfur, and Silicon and the Related Elements
- Vol. 196 (4) , 389-397
Synthesis, α -amylase inhibitory activity evaluation and in silico molecular docking study of some new phosphoramidates containing heterocyclic ring
We have synthesized a series of phosphoramidates containing a heterocyclic moiety with good yields (88–95%) by the reaction of (E)-5-benzylidene-3-((2-hydroxyethoxy)methyl)thiazolidine-2,4-dione with ethyl phosphorodichloridate followed by the reaction with various heterocyclic amines. The designed compounds were primarily screened for their ability to inhibit pancreatic α-amylase enzyme using in silico molecular docking approach. The compounds with good binding energies (−8.0 to −6.9 kcal/mol) when compared with standard drug, acarbose (−8.0 kcal/mol) were prompted for the synthesis. The structures of the newly prepared compounds were confirmed by their spectroscopic analyses. They were further screened in vitro for their inhibition toward α-amylase enzyme using acarbose as standard drug. All compounds exhibited moderate to good inhibition potential with IC50 values in the range of 54.14 ± 0.35 to 185.04 ± 0.53 µg/mL when compared with the standard drug (IC50, 50.47 ± 0.28 µg/mL). Especially, the compound (E)-2-((5-benzylidene-2,4-dioxothiazolidin-3-yl)methoxy)ethyl ethyl 1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-ylphosphoramidate (6f) (IC50, 54.14 ± 0.35 µg/mL) and (E)-2-((5-benzylidene-2,4-dioxothiazolidin-3-yl)methoxy)ethyl ethyl benzo[d]thiazol-2-ylphosphoramidate (6c) (IC50, 57.02 ± 0.32 µg/mL) exhibited the best inhibition among the synthesized compounds. Graphical abstract
- 23 November 2020
- Published by Taylor & Francis in Phosphorus, Sulfur, and Silicon and the Related Elements
- Vol. 196 (4) , 389-397
Synthesis, α -amylase inhibitory activity evaluation and in silico molecular docking study of some new phosphoramidates containing heterocyclic ring
We have synthesized a series of phosphoramidates containing a heterocyclic moiety with good yields (88–95%) by the reaction of (E)-5-benzylidene-3-((2-hydroxyethoxy)methyl)thiazolidine-2,4-dione with ethyl phosphorodichloridate followed by the reaction with various heterocyclic amines. The designed compounds were primarily screened for their ability to inhibit pancreatic α-amylase enzyme using in silico molecular docking approach. The compounds with good binding energies (−8.0 to −6.9 kcal/mol) when compared with standard drug, acarbose (−8.0 kcal/mol) were prompted for the synthesis. The structures of the newly prepared compounds were confirmed by their spectroscopic analyses. They were further screened in vitro for their inhibition toward α-amylase enzyme using acarbose as standard drug. All compounds exhibited moderate to good inhibition potential with IC50 values in the range of 54.14 ± 0.35 to 185.04 ± 0.53 µg/mL when compared with the standard drug (IC50, 50.47 ± 0.28 µg/mL). Especially, the compound (E)-2-((5-benzylidene-2,4-dioxothiazolidin-3-yl)methoxy)ethyl ethyl 1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-ylphosphoramidate (6f) (IC50, 54.14 ± 0.35 µg/mL) and (E)-2-((5-benzylidene-2,4-dioxothiazolidin-3-yl)methoxy)ethyl ethyl benzo[d]thiazol-2-ylphosphoramidate (6c) (IC50, 57.02 ± 0.32 µg/mL) exhibited the best inhibition among the synthesized compounds. Graphical abstract
- 16 March 2020
- Published by Taylor & Francis in Phosphorus, Sulfur, and Silicon and the Related Elements
- Vol. 195 (7) , 586-591
Synthesis and anti-diabetic activity evaluation of phosphonates containing thiazolidinedione moiety
A sequence of substituted phosphonates containing the thiazolidinedione moiety was synthesized with good yields. The structures of all the synthesized compounds were confirmed by NMR (31P, 1H and 13C) and IR spectroscopy, mass spectrometry and C, H, N elemental analyses. In silico molecular docking study was also carried out to evaluate their interaction and binding modes on ligands against human PPAR γ protein for their anti-diabetic activity. From the docking results, it was determined that the compounds (Z)-dimethyl 5-(3-nitrobenzylidene)−2,4-dioxothiazolidin-3-ylphosphonate (7a), (Z)-dimethyl 5-(3-chloro-4-fluorobenzylidene)−2,4-dioxothiazolidin-3-ylphosphonate (7f), (Z)-dimethyl 5-(2,4-dichlorobenzylidene)−2,4-dioxothiazolidin-3-ylphosphonate (7e) and (Z)-dimethyl 5-((5-methoxypyridin-2-yl)methylene)−2,4-dioxothiazolidin-3-ylphosphonate (7j) have shown better binding energies (−7.8, −7.6, −7.5 and −7.6 Kcal/mol) with the target gene, PPAR γ than the reference drug, Rosiglitazone (−7.4 Kcal/mol). In vitro anti-diabetic activity of the title compounds was also screened by standard α-amylase inhibition assay. Some of the tested compounds proved to possess promising activity when compared with the reference drug.
- 16 March 2020
- Published by Taylor & Francis in Phosphorus, Sulfur, and Silicon and the Related Elements
- Vol. 195 (7) , 586-591
Synthesis and anti-diabetic activity evaluation of phosphonates containing thiazolidinedione moiety
A sequence of substituted phosphonates containing the thiazolidinedione moiety was synthesized with good yields. The structures of all the synthesized compounds were confirmed by NMR (31P, 1H and 13C) and IR spectroscopy, mass spectrometry and C, H, N elemental analyses. In silico molecular docking study was also carried out to evaluate their interaction and binding modes on ligands against human PPAR γ protein for their anti-diabetic activity. From the docking results, it was determined that the compounds (Z)-dimethyl 5-(3-nitrobenzylidene)−2,4-dioxothiazolidin-3-ylphosphonate (7a), (Z)-dimethyl 5-(3-chloro-4-fluorobenzylidene)−2,4-dioxothiazolidin-3-ylphosphonate (7f), (Z)-dimethyl 5-(2,4-dichlorobenzylidene)−2,4-dioxothiazolidin-3-ylphosphonate (7e) and (Z)-dimethyl 5-((5-methoxypyridin-2-yl)methylene)−2,4-dioxothiazolidin-3-ylphosphonate (7j) have shown better binding energies (−7.8, −7.6, −7.5 and −7.6 Kcal/mol) with the target gene, PPAR γ than the reference drug, Rosiglitazone (−7.4 Kcal/mol). In vitro anti-diabetic activity of the title compounds was also screened by standard α-amylase inhibition assay. Some of the tested compounds proved to possess promising activity when compared with the reference drug.
- Open Access
- 1 January 2020
- Published by Walter de Gruyter GmbH in Main Group Metal Chemistry
- Vol. 43 (1) , 147-153
Ultrasound-promoted solvent-free synthesis of some new α -aminophosphonates as potential antioxidants
Ultrasonic irradiation has been adopted in order to achieve an efficient synthesis of some novel α- aminophosphonates by Pudovik reaction. Major benefits of this method are as follows: eco-friendly, free of catalyst, high yielding, uncomplicated work-up procedure, short reaction time, and solvent free condition. Spectral characterisation and elemental analysis of the synthesized samples was carried out. In vitro antioxidant activity of the title compounds was screened by DPPH˙, O 2- ˙ and NO˙ scavenging methods. Good activity was shown by most of the compounds as compared with the standards.
- 1 January 2020
- Published by Walter de Gruyter GmbH in Main Group Metal Chemistry
- Vol. 43 (1) , 147-153
Open AccessUltrasound-promoted solvent-free synthesis of some new α -aminophosphonates as potential antioxidants
Ultrasonic irradiation has been adopted in order to achieve an efficient synthesis of some novel α- aminophosphonates by Pudovik reaction. Major benefits of this method are as follows: eco-friendly, free of catalyst, high yielding, uncomplicated work-up procedure, short reaction time, and solvent free condition. Spectral characterisation and elemental analysis of the synthesized samples was carried out. In vitro antioxidant activity of the title compounds was screened by DPPH˙, O 2- ˙ and NO˙ scavenging methods. Good activity was shown by most of the compounds as compared with the standards.